These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35892906)

  • 1. Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review.
    Leung J; Lee S; Zhou J; Jeevaratnam K; Lakhani I; Radford D; Coakley-Youngs E; Pay L; Çinier G; Altinsoy M; Behnoush AH; Mahmoudi E; Matusik PT; Bazoukis G; Garcia-Zamora S; Zeng S; Chen Z; Xia Y; Liu T; Tse G
    Life (Basel); 2022 Jul; 12(8):. PubMed ID: 35892906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
    Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia.
    Yan Y; Tang L; Wang X; Zhou K; Hu F; Duan H; Liu X; Hua Y; Wang C
    Orphanet J Rare Dis; 2023 Dec; 18(1):380. PubMed ID: 38053087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.
    Márquez MF; Totomoch-Serra A; Rueda A; Avelino-Cruz JE; Gallegos-Cortez A
    Rev Invest Clin; 2019; 71(4):226-236. PubMed ID: 31448784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H; Knollmann BC
    J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
    Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
    J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Peltenburg PJ; Kallas D; Bos JM; Lieve KVV; Franciosi S; Roston TM; Denjoy I; Sorensen KB; Ohno S; Roses-Noguer F; Aiba T; Maltret A; LaPage MJ; Atallah J; Giudicessi JR; Clur SB; Blom NA; Tanck M; Extramiana F; Kato K; Barc J; Borggrefe M; Behr ER; Sarquella-Brugada G; Tfelt-Hansen J; Zorio E; Swan H; Kammeraad JAE; Krahn AD; Davis A; Sacher F; Schwartz PJ; Roberts JD; Skinner JR; van den Berg MP; Kannankeril PJ; Drago F; Robyns T; Haugaa K; Tavacova T; Semsarian C; Till J; Probst V; Brugada R; Shimizu W; Horie M; Leenhardt A; Ackerman MJ; Sanatani S; van der Werf C; Wilde AAM
    Circulation; 2022 Feb; 145(5):333-344. PubMed ID: 34874747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rare Case of RYR2 Mutation Causing Sudden Cardiac Arrest Due to Catecholaminergic Polymorphic Ventricular Tachycardia.
    Vemireddy LP; Aqeel A; Ying GW; Majlesi D; Woo V
    Cureus; 2021 Feb; 13(2):e13417. PubMed ID: 33763313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catecholaminergic Polymorphic Ventricular Tachycardia and Gene Therapy: A Comprehensive Review of the Literature.
    Henriquez E; Hernandez EA; Mundla SR; Wankhade DH; Saad M; Ketha SS; Penke Y; Martinez GC; Ahmed FS; Hussain MS
    Cureus; 2023 Oct; 15(10):e47974. PubMed ID: 38034271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
    Imberti JF; Underwood K; Mazzanti A; Priori SG
    Heart Lung Circ; 2016 Aug; 25(8):777-83. PubMed ID: 26948768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
    Mazzanti A; Kukavica D; Trancuccio A; Memmi M; Bloise R; Gambelli P; Marino M; Ortíz-Genga M; Morini M; Monteforte N; Giordano U; Keegan R; Tomasi L; Anastasakis A; Davis AM; Shimizu W; Blom NA; Santiago DJ; Napolitano C; Monserrat L; Priori SG
    JAMA Cardiol; 2022 May; 7(5):504-512. PubMed ID: 35353122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current topics in catecholaminergic polymorphic ventricular tachycardia.
    Sumitomo N
    J Arrhythm; 2016 Oct; 32(5):344-351. PubMed ID: 27761157
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.